Eyenovia Inc (NASDAQ:EYEN) major shareholder Stuart M. Grant purchased 6,700 shares of the stock in a transaction dated Monday, October 14th. The stock was acquired at an average price of $3.25 per share, for a total transaction of $21,775.00. Following the completion of the transaction, the insider now directly owns 2,226,183 shares of the company’s stock, valued at $7,235,094.75. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Major shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.
Shares of NASDAQ EYEN opened at $2.83 on Monday. Eyenovia Inc has a 1 year low of $2.40 and a 1 year high of $6.98. The firm’s 50 day moving average price is $3.22 and its 200 day moving average price is $3.97. The firm has a market cap of $46.04 million, a P/E ratio of -1.55 and a beta of 1.03.
Eyenovia (NASDAQ:EYEN) last announced its earnings results on Wednesday, November 13th. The company reported ($0.29) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.34) by $0.05. Analysts anticipate that Eyenovia Inc will post -1.51 EPS for the current fiscal year.
Several research firms have recently commented on EYEN. HC Wainwright reiterated a “buy” rating and issued a $10.00 price target on shares of Eyenovia in a research report on Friday. ValuEngine lowered shares of Eyenovia from a “buy” rating to a “hold” rating in a research report on Thursday. Finally, Zacks Investment Research upgraded shares of Eyenovia from a “hold” rating to a “buy” rating and set a $3.75 price target on the stock in a research report on Friday, August 16th.
Eyenovia, Inc, a clinical stage biopharmaceutical company, engages in developing a pipeline of ophthalmology products in the United States. It is developing MicroProst, which is in Phase III clinical trials for the treatment of chronic angle closure glaucoma; MicroStat, which is in Phase III clinical trials for the treatment of mydriasis; MicroTears for the treatment of dry eye; and MicroPine for the treatment of myopia.
Read More: The four types of profit margin
Receive News & Ratings for Eyenovia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyenovia and related companies with MarketBeat.com's FREE daily email newsletter.